Pharmacy Times May 20, 2022

Agnieszka Sekula and Prash Puspanathan, MD, co-founders of Enosis Therapeutics, discuss the impact of therapeutic environment on the pharmaceutical effects of psychedelics.

Pharmacy Times interviewed Agnieszka Sekula and Prash Puspanathan, MD, co-founders of Enosis Therapeutics, an Australia-based medical technology and research company investigating the introduction of virtual reality (VR) into the psychedelic therapy space.

Alana Hippensteele: Hi, I’m Alana Hippensteele with Pharmacy Times, and joining me Agnieszka Sekula and Prash Puspanathan, MD, who are co-founders of Enosis Therapeutics, which is an Australia-based medical technology and research company investigating the introduction of virtual reality, or VR, into the psychedelic therapy space. They recently published the first academic paper examining the synergistic applications of VR technology and psychedelic-assisted psychotherapy to explore how...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Interview / Q&A, Mental Health, Metaverse/VR, Pharma, Pharma / Biotech, Provider, Technology, Trends
Related Articles:
FDA spends $1.2M on VR-enabled hub to spur development of at-home care devices
Old Dominion University, HaptX, Georgia Tech receive grant for VR for the visually impaired
FDA initiative puts AR/VR at heart of home health drive
Meta's Reality Labs posts $3.85 billion loss in first quarter
Meta Aims to Ignite Enterprise Productivity With Open Metaverse OS

Share This Article